Supernus Pharmaceuticals Inc (SUPN)
Supernus Pharmaceuticals, Inc. is a NASDAQ-listed common equity security tied to a biopharmaceutical company focused on developing and commercializing treatments for central nervous system disorders in the United States. Its marketed products include Qelbree for attention-deficit hyperactivity disorder, GOCOVRI for dyskinesia in Parkinson’s disease, Oxtellar XR for partial-onset seizures, APOKYN for intermittent hypomobility in advanced Parkinson’s disease, Trokendi XR for epilepsy and migraine prevention, XADAGO for Parkinson’s disease off episodes, and MYOBLOC for cervical dystonia and chronic sialorrhea. The company also recently received FDA approval for ONAPGO, which is being developed for motor fluctuations in adults with advanced Parkinson’s disease. Supernus continues to advance its pipeline with SPN-817, SPN-820, and SPN-443, and it markets products through wholesalers, specialty pharmacies, and distributors. The company was incorporated in 2005 and is based in Rockville, Maryland.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-SUPN
|
$53.49
|
12.5% Upside
|
Fair
|
$63.50
|
33.6% Upside
|
Undervalued
|
Good
|
—
|
—
|
—
|
0.0%
|
August 11, 2026
|
-94.8x
|
2.6x
|
3.5x
|
2.752 B
|
2.408 B
|
1.5%
|
89.8%
|
6.3
|
—
|
-283.4%
|
